A new FDA-authorized COVID-19 test doesn’t need a lab and can produce results in just 5 minutes – TechCrunch
There’s a new COVID-19 test from healthcare know-how maker Abbott that appears to be the quickest but in phrases of manufacturing results, and that can achieve this on the spot proper at point-of-care, with out requiring a spherical journey to a lab. This test for the novel coronavirus inflicting the present international pandemic has acquired emergency clearance to be used by the U.S. Food and Drug Administration, and will start manufacturing subsequent week, with output of 50,000 per day potential beginning subsequent week.
The new Abbott ID NOW COVID-19 test makes use of the Abbott ID NOW diagnostics platform, which is basically a lab-in-a-box that’s roughly the dimensions of a small kitchen equipment. It’s dimension, and the truth that it can produce both a optimistic outcome in just 5 minutes, or a adverse one in underneath 15, imply that it may very well be a very helpful means to increase coronavirus testing past its present availability to extra locations together with clinics and physician’s places of work, and minimize down on wait instances each in phrases of getting examined and receiving a analysis.
Unlike the fast exams which were used in different nations, and that acquired a new sort of authorization underneath an FDA guideline that doesn’t verify the accuracy fo the results, this fast testing answer makes use of the molecular testing technique, which works with saliva and mucus samples swabbed from a affected person. This signifies that it really works by figuring out a portion of the virus’ DNA in a affected person, which implies it’s a lot better at detecting the precise presence of the virus throughout an infection, whereas different exams that search the blood for antibodies which can be used in point-of-care settings can solely detect antibodies, which is likely to be current in recovered sufferers who don’t actively have the virus.
The excellent news for availability of this test is that ID NOW, the from Abbott that it runs on, already “holds the largest molecular point-of-care footprint in the U.S.,” and is “widely available” throughout physician’s places of work, pressing care clinics, emergency rooms and different medical amenities.
In whole, Abbott now says that it believes it can produce 5 million exams in April, cut up between these new fast exams and the lab exams that it acquired emergency use authorization for by the FDA on March 18.
Testing has been one of many early issues confronted by the U.S. in phrases of getting a deal with on the coronavirus pandemic: The nation has lagged behind different nations globally in phrases of per capita exams performed, which specialists say has hampered its potential to correctly observe and hint the unfold of the virus and its ensuing respiratory illness. Patients have reported having to go to excessive lengths to obtain a test, and endure lengthy waits for results, even in instances the place publicity was doubtless and their signs match the COVID-19 profile.